case_images: PMC6877974_01
case_images: Patient 1 with a 24 mm in maximal diameter keratoacanthoma. The patient was treated with weekly sessions of cryosurgery (liquid N2, open spray, 2 cycles of 15 sec each), intralesional methotrexate (7.5 mg/weekly sessions) (Panels a-d) and daily application of imiquimod. Panel a: The tumor at baseline. Panels b-d: The tumor at weekly intervals at the days of cryosurgery and intralesional methotrexate. Panel e: Gradual tumor involution is achieved and the patient is treated with daily imiquimod for another week (35 days imiquimod in total). Panel f: The tumor has cleared and a deep scar has remained, representing the "tumor ghost", i.e., the area destroyed by the rapidly expanding keratoacanthoma. Photographs were acquired with modification of a previously used equipment employing a Nikon D610 camera with a spatial resolution of 6016 x 4016 pixels. A 60 mm prime lens was adapted with a vertical polarized filter and a SIGMA EM-140 Macro ring flash with an additional vertical polarized filter. The photographs were taken with the axons of polarization of the two filters in vertical position to each other for cross-polarization to enhance the visualization of the vascular bed.
case_images: CRIDM2019-3489748.001.jpg
case_images: PMC6877974_01_CRIDM2019-3489748.001.jpg
case_images: fig1
case_images: Patient 1 (Figure 1).
case_images: PMC6877974_02
case_images: PMC6877974_03
case_images: Patient 3. Panel a: The patient at presentation with two keratoacantoma lesions (arrays). Scars from previous surgeries for the same diagnosis are evident. Panel b: At 12 months follow-up the two lesions in complete remission with a swallow scar. Meanwhile a new lesion has appeared (arrow). Panel c: The patient at the 18 months follow-up. All photographs are taken with parallel polarization to increase the perception of skin relief. For details of photography see Figure 1.
case_images: CRIDM2019-3489748.002.jpg
case_images: PMC6877974_03_CRIDM2019-3489748.002.jpg
case_images: fig2
case_images: Patient 3 (Figure 2).